Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.

CD5 status in other subtypes, including PTCL-NOS (n = 41), ALK-mutated/wt ALCL (ALK-mut: n = 16, WT: n = 28), and ENKTCL (n = 22) did not reach statistical significance ( Figure 4 A,B).

also in 111,027 other papers

There was a positive trend towards improved outcome in CD5- patients; the 5-year survival for CD5- patients (n = 72) was 58.2% (95 CI: 46.7–72.6%) compared to 49.9% (95 CI: 39.8–62.5%) in CD5 patients ( Figure 3 B).

also in 11,005 other papers